Clinical applications of positron emission tomography in hepatic tumors

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 611-617

  Shiomi, Susumu ^a   Kawabe, Joji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Fluorodeoxyglucose; Hepatocellular carcinoma; Metastatic liver cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOSE TRANSPORTER;

ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GENE OVEREXPRESSION; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW;

EID: 79959774975     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00819.x     Document Type: Review

References (52)

1. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S A 2000; 97: 9226-33.
2. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous, and neoplastic tissues. Cancer Res 1955; 15: 105-8.
3. Torizuka T, Tamaki N, Inokuma T etal. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-16.
4. Delbeke D, Martin WH, Sandler MP etal. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133: 510-15.
5. Khan MA, Combs CS, Brunt EM etal. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-7.
6. Torizuka T, Tamaki N, Inokuma T etal. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-9.
7. Iwata Y, Shiomi S, Sasaki N etal. Clinical usefulness of positron emission tomography with fluorifluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000; 14: 121-6.
8. Trojan J, Schroeder O, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-19.
9. Shiomi S, Nishiguchi S, Ishizu H etal. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877-80.
10. Miles KA, Williams RE. Warburg revisited: imaging tumor blood flow and metabolism. Cancer Imaging 2008; 25: 81-6.
11. Fukuda K, Taniguchi H, Koh T, Kunishima S, Yamagishi H. Relationship between oxygen and glucose metabolism in human liver tumors: positron emission tomography using O-15 and F-18 deoxyglucose. Nucl Med Commun 2003; 25: 577-83.
12. Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun 2005; 26: 315-21.
13. Hatano E, Ikai I, Higashi T etal. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006; 30: 1736-41.
14. Higashi T, Hatano E, Ikai I etal. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010; 37: 468-82.
15. Anderson GS, Brinkmann F, Soulen MC etal. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003; 28: 192-7.
16. Han AR, Gwak GY, Choi MS etal. The clinical value of 18F-FDG PET/CT for investigating unexplained serum AFP elevation Following interventional therapy for hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1111-16.
17. Kawamura E, Habu D, Ohfuji S etal. Clinical role of FDG-PET for HCC: relationship of glucose metabolic indicator to Japan Integrated Staging (JIS) score. Hepatogastroenterology 2008; 55: 582-6.
18. Yang SH, Suh KS, Lee HW etal. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006; 12: 1655-60.
19. Lee JW, Paeng JC, Kang KW etal. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682-7.
20. Sugiyama M, Sakahara H, Torizuka T etal. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39: 961-8.
21. Kawaoka T, Aikata H, Tasaki S etal. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009; 39: 134-42.
22. Park JW, Kim JH, Kim SK etal. A prospective evaluation of F-18 FDG and C-11 acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49: 1912-21.
23. Seo S, Hatano E, Higashi T etal. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 427-33.
24. Abdel-Nabi H, Doerr RJ, Lamonica DM etal. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxy glucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755-608.
25. Kinkel K, Lu Y, Both M etal. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224: 748-56.
26. Delbeke D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer lymphoma and melanoma. J Nucl Med 1999; 40: 591-603.
27. Truant S, Huglo D, Hebbar M, Emst O, Steinling M, Pruvot FR. Prospective evaluation of the impact of [F-18]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-9.
28. Chua SC, Groves AM, Kayani I etal. The impact of F-18 FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007; 34: 1906-14.
29. Bang S, Chung HW, Park SW etal. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006; 40: 923-9.
30. Donati OF, Hany TF, Reiner CS etal. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with F-18 FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med 2010; 51: 692-9.
31. Anderson CD, Rice MH, Pinson CW etal. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-7.
32. Petrowsky H, Wildbrett P, Husarik DB etal. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45: 43-50.
33. Prytz H, Keiding S, Bjornsson E. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006; 44: 1572-80.
34. Shiomi S, Sasaki N, Kawashima D etal. Combined hepatocellular carcinoma and cholangiocarcinoma with high F-18 fluorodeoxy glucose positron emission tomography uptake. Clin Nucl Med 1999; 24: 370-1.
35. Nishiguchi S, Shiomi S, Ofuji S etal. Leiomyosarcoma of the liver detected by high F-18 fluorodeoxyglucose positron emission tomographic uptake. Clin Nucl Med 2001; 26: 798-9.
36. Kitapoci MT, Akkas BE, Gullu I, Sckmensuer C. FDG-PET/CT in the evaluation of epithelioid hemangioendothelioma of the liver: the role of dual-time-point imaging. A case presentation and review of the literature. Ann Nucl Med 2010; 24: 549-53.
37. Ho C-L, Yu SCH, Yeung DWC. C-11 acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213-21.
38. Ho C-L, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48: 902-9.
39. Park JW, Kim JH, Kim SK etal. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular. J Nucl Med 2008; 49: 1912-21.
40. Yamamoto Y, Nishiyama Y, Kameyama R etal. Detection of hepatocellular carcinoma using C-11 choline PET: comparison with F-18 FDG PET. J Nucl Med 2008; 49: 1245-8.
41. Talbot JN, Fartoux L, Balogova S etal. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51: 1699-706.
42. Eckel F, Herrmann K, Schmidt S etal. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker F-18 fluorothymidine. J Nucl Med 2009; 50: 1441-7.
43. Yen RF, Chen CY, Chen MF etal. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun 2010; 31: 637-45.
44. Nakamoto Y, Tatsumi M, Cohade C, Osman MM, Marshall LT, Wahl RL. Accuracy of image fusion of normal upper abdominal organs visualized with PET/CT. Eur J Nucl Med Mol Imaging 2003; 30: 597-602.
45. Osman MM, Cohade C, Nakamoto Y, Marshall LT, Leal JP, Wahl RL. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 2003; 44: 240-3.
46. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? F-18-FDG and CT contrast agents in dual-modality F-18-FDG PET/CT. J Nucl Med 2004; 45: 56S-5S.
47. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003; 28: 192-7.
48. Shiga T, Morimoto Y, Kubo N etal. A New PET scanner with semiconductor detectors enables better Identification of intratumoral inhomogeneity. J Nucl Med 2009; 50: 148-55.
49. Pichler BJ, Kolb A, Nagaele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010; 51: 333-6.
50. Paul AK, Abdel-Nabi H. Cancer imaging agents for positron emission tomography: beyond FDG. Curr Med Imaging Rev 2007; 3: 178-85.
51. 2O. J Nucl Med 2004; 45: 1851-9.
52. Yagle KJ, Eary JF, Tait JF etal. Evaluation of F-18-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46: 658-66.